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ABSTRACT 
  
Dopamine related disorders usually respond to dopaminergic drugs, 
but not all symptoms are equally responsive. In Parkinson’s disease 
(PD) in particular, axial symptoms resulting in impaired gait and pos-
tural control are difficult to treat. Stochastic vestibular stimulation 
(SVS) has been put forward as a method to improve CNS function in 
dopamine related disorders, but the mechanisms of action are not 
well understood. 
This thesis aimed to investigate the effects of SVS on neuronal 
brain activity and to evaluate the possible enhancing effect of SVS on 
motor control in PD and on cognitive functions and motor learning in 
Attention deficit hyperactivity disorder (ADHD).    
Behavioural tests were conducted in the 6-OHDA rat model of 
PD using the accelerating Rotarod and the Montoya skilled reach test 
to evaluate the effect of SVS on motor control. The effect of SVS on 
brain activity was assessed using in vivo microdialysis and immuno-
histochemistry. We evaluated the effect of SVS on postural control 
and Parkinsonism in patients with PD and the effect of SVS on cogni-
tive function in people with ADHD. 
 
 
 
 
 
 
 
 
 
 
The behavioural animal studies indicate that SVS may have an 
enhancing effect on locomotion, but not skilled forepaw function. SVS 
increased GABA transmission in the ipsilesional substantia nigra 
(SN) and may have a rebalancing effect on dysfunctional brain activi-
ty. SVS increased c-Fos activity more than levodopa and saline in the 
vestibular nucleus of all animals. c-Fos expression was also higher in 
this region in the 6-OHDA lesioned than in shamlesioned animals, 
supporting the theory that SVS may have larger effects in the dopa-
mine depleted brain. SVS increased c-Fos expression in the habenula 
nucleus substantially more than levodopa did. Furthermore, SVS and 
levodopa had similar effects on many brain regions, including the 
striatum, where saline had no effect. The clinical studies revealed im-
provement of postural control in PD during SVS. There was a trend 
towards reduced Parkinsonism during SVS when off levodopa. No 
substantial effects were found on cognitive performance in ADHD.      
In PD, SVS may improve motor control by inhibiting the over-
active SN, possibly through a non-dopaminergic modulatory pathway 
involving increased neurotransmission in the habenula nucleus. SVS 
could be trialled in larger studies to evaluate long-term effects on 
treatment resistant axial symptoms associated with PD. 
Keywords 
Vestibular stimulation, Microdialysis, GABA, Substantia nigra, c-Fos, 
Habenula nucleus  
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 SAMMANFATTNING PÅ 
SVENSKA 
Tillgängliga behandlingar vid Parkinsons sjukdom (PD) är vanligen 
mer effektiva för rörelsesymptom i extremiteter och mindre effektiva 
för axiella rörelsesymptom, såsom balanssvårigheter. Vidare är icke-
motoriska och neuropsykiatriska  symptom vid PD mer eller mindre 
resistenta mot de vanligaste behandlingarna, levodopa och djup 
hjärnstimulering (deep brain stimulation – DBS). Levodopa, en 
dopaminerg behandling, kan framkalla överrörlighet, dyskinesi, och 
framkalla eller försämra kognitiva funktionsnedsättningar.  
Galvanisk stokastisk vestibulär stimulering (SVS) med strömstyrkor 
nära tröskeln för aktivering av balansreaktioner, aktiverar 
balansnerverna genom en elektrisk ström genom de bilaterala 
vestibulära perifera organen. Det finns tidigare rapporter att balans 
kan förbättras av SVS, och även  förbättrad kognitiv funktion och 
förbättrade autonoma kardiovaskulära funktioner vid 
neurodegenerativa sjukdomar. Dessutom har man funnit att 
stimulering av hörselsystemet med stokastiskt ljud (vitt brus) kan 
förbättra den kognitiva förmågan hos personer med Attention Deficit 
Hyperactivity Disorder (ADHD). Det övergripande syftet med denna 
avhandling var att utvärdera effekterna av galvanisk SVS i förhållande 
till levodopa i både kliniska och prekliniska studier, och att undersöka 
de möjliga mekanismerna bakom dessa effekter. Dessutom var vi 
intresserade av huruvida SVS har samma positiva resultat på 
kognitiva funktioner som stokastiskt ljud.  
I den första studien (delarbete I) undersökte vi effekten av SVS och 
levodopa på lokomotion och finmotorik i en råttmodell av PD där 
dopaminsystemet slagits ut i ena hjärnhalvan med toxinet 6-OHDA. 
Vidare studerade vi effekten av SVS på frisättning av signalämnen 
(särskilt dopamin och GABA) i intakta och i 6-OHDA 
hemilesionerade råttor. Effekterna av SVS jämfördes med de akuta 
effekterna av en dos levodopa. Vi fann att SVS förbättrade förmågan 
att hålla sig kvar på en roterande stav (lokomotion) jämfört med 
shamSVS (icke-aktiv stimulering) i hemilesionerade råttor. 
Finmotorik påverkades inte av SVS. Vi visade också en ökad 
 
 
 
 
frisättning av GABA i substantia nigra pars reticulata i intakta råttor 
och en balansering av GABA-frisättning i samma kärnor i 
hemilesionerade råttor. Dopaminfrisättning förändrades dock inte av 
SVS i några djur, vilket tyder på att effekten av SVS inte medieras av 
dopaminfrisättning.  
I den andra studien (delarbete II) analyserade vi effekten av SVS eller 
levodopa i olika hjärnregioner genom att kvantifiera uttrycket av 
proteinprodukten av c-Fos-genen, som är en markör för ökad 
nervcellsaktivitet. Vi upptäckte att SVS ledde till en ökad c-Fos-
aktivitet i de vestibulära kärnorna i 6-OHDA djuren jämfört med 
sham-lesionerade djur. Ett intressant fynd var att SVS även ökade 
aktiviteten i laterala habenula-kärnan, både i 6-OHDA och sham-
lesionerade djur, medan levodopa- och koksaltinjektioner hade 
minimala effekter. Dessa resultat tyder på att SVS kan har större 
effekt på det vestibulära systemet vid hypodopaminerga tillstånd, 
samt att habenula kärnan skulle kunna vara involverad.  
I den tredje studien (delarbete III) undersökte vi om SVS och 
levodopa kan förbättra balanssvårigheter hos patienter med PD i en 
randomiserad cross-over pilotstudie. SVS förbättrade den tid det tog 
att återfå balansen efter en påtvingad rörelse bakåt. De olika testerna 
antydde även en trend till minskade Parkinsonssymptom under SVS 
när patienten var utan samtidig dopaminerg medicin. 
Vi undersökte effekterna av SVS på kognitiv förmåga hos deltagare 
med ADHD i den sista studien (delarbete IV). I en pilotstudie med en 
randomiserad cross-over design fick  forskningspersoner med ADHD 
genomgå tre tester (Rey Auditory Verbal Learning Test, Span-board 
och Flower trail test), under antingen SVS eller shamSVS. Vi kunde 
inte påvisa några positiva effekter av SVS på arbetsminne, 
handmotorik eller inlärning/minne.  
Sammanfattningsvis verkar SVS ha olika effekter i den intakta 
hjärnan i jämförelse med en hypodopaminerg hjärna. Neurokemiska 
djurdata indikerar att SVS kan balansera aktiviteten i de basala 
ganglierna. Immunohistokemiska djurdata stöder hypotesen att SVS 
har större effekter i en hypodopaminerg hjärna, och indikerar att den 
aktiverar neuroner i många hjärnregioner (bland annat striatum) i 
likhet med levodopa, och slutligen att habenula-kärnan kan vara 
involverad i dess mechanism. Klinisk data pekar på små positiva 
effekter på postural balans vid PD, men inte på tydligt förbättrad 
kognitiv förmåga vid ADHD.         
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ABBREVIATIONS 
Acb    Nucleus Accumbens  
ADHD  Attention Deficit Hyperactivity Disorder 
BIC    Brachium Inferior Colliculus  
CnF    Cuneiform nucleus  
CPu    CaudoPutamen (Dorsal striatum) 
DBS   Deep Brain Stimulation 
DP    Dorsal Peduncular 
GABA  Gamma-Amino-Butyric Acid 
GP(e/i)  Globus Pallidus (external/internal segment) 
ILL    Intermediate nucleus of Lateral Lemniscus 
LHb    Lateral Habenula nucleus 
MVePC  Medial Vestibular nucleus - Parvocellular part 
PD   Parkinson’s Disease  
PPN    Pedunculopontine nucleus 
Rt    Reticular thalamic nucleus  
RVLM   Ventrolateral Medullary Region 
SN(c/r) Substantia Nigra (compacta/reticulate) 
STN    Subthalamic nucleus  
SVS   Stochastic Vestibular Stimulation 
VM    Ventromedial thalamus  
VTA   Ventral Tegmental Area 
6-OHDA 6-hydroxydopamine 
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INTRODUCTION 
A defining feature of neurodegenerative disorders is the progressive 
death of nerve cells in central and/or peripheral structures of the nervous 
system. Common to several neurodegenerative disorders are difficulties 
in motor control as well as various degrees of cognitive impairment. Idio-
pathic Parkinson’s disease (PD) is one of the most common neurodegen-
erative disorders. The primary neuropathological characteristic feature of 
PD is the progressive degeneration of dopaminergic neurons in the sub-
stantia nigra pars compacta (SNc). Attention deficit hyperactivity disor-
der (ADHD) is not a neurodegenerative disorder, but some of the 
symptoms in ADHD seem to be related to the dopamine pathways. The 
pathophysiology of ADHD is however not fully known.      
In 1958 Carlsson and colleagues [1] discovered that dopamine is a neuro-
transmitter in its own right and not just the precursor to adrenaline and 
noradrenaline. Not long after this discovery, it was established that do-
paminergic cell bodies are primarily found in particular midbrain areas, 
namely the ventral tegmental area (VTA) and the substantia nigra (SN) 
[2, 3]. Since then, research around the function and mechanism of neuro-
transmitters has boomed, contributing to a research field yet expanding. 
As dopamine is involved in an array of networks within the nervous sys-
tem, the abnormal function of this neurotransmitter is the ground for 
symptom profiles ranging from mild cognitive impairment to severe mo-
tor dysfunction.  
The most noted motor difficulties in PD include bradykinesia, rest tremor 
and rigidity. These normally respond well to levodopa, a precursor to do-
pamine which restores some of the dopamine loss in the hypo-
dopaminergic brain. Many of these motor symptoms appear to be a direct 
consequence of dopaminergic loss in the central nervous system [4]. Oth-
er motor difficulties, such as postural instability, balance problems, falls 
and freezing of gait are assumed to be partially indirect consequences of 
dopaminergic loss. These respond less to levodopa medication and will 
typically develop in later stages of the disease [5]. Long-term use of levo-
dopa medication can trigger other symptoms as well, such as dyskinesia 
and weaker impulse control [6, 7]. Furthermore, non-motor difficulties 
can follow due to neurotransmitter deficiencies in the central and          
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peripheral nervous system. These include mental problems such as cogni-
tive decline, sleep disturbances and depression, as well as autonomic 
problems such as constipation, postural hypotension and sexual disturb-
ances [5, 8, 9]. These symptoms often appear years before motor symp-
toms do, and are a challenge to treat effectively. Mild cognitive 
impairment in PD for instance has a prevalence of 15-40% at the time of 
diagnosis [10]. Many, but not all, of the cognitive levodopa non-
responsive symptoms can be categorised as executive dysfunctions. In 
some respects, the cognitive problems of patients with PD resemble the 
cognitive impairments in ADHD. ADHD can be defined as a disorder 
which primarily affects the executive functions such as cognition, atten-
tion and motor learning as well as self-control [11].  
In the late nineteenth century, the neurologist Charcot discovered that 
his PD patients experienced reduced resting tremor symptoms during 
train journeys. He proposed that the effect was induced by vibrations and 
therefore created a vibrating therapy chair for these patients and reported 
improvements in symptoms. Not long after, a vibrating helmet followed 
[12]. The principles of vibration for relief of motor symptoms have been 
tested in recent years with varying outcomes [13, 14]. One study found 
some improvement of PD symptomatology, however the improvements 
were generated equally by the relaxing auditory stimuli applied at the 
same time as vibration [15]. There is consequently some support for the 
idea that sensory stimuli can improve some aspects of PD symptoms.   
It is possible that some of the dysfunctional executive functions in PD and 
other dopamine related disorders are in part an effect of inadequate inte-
gration of the sensorimotor and proprioceptive feedback system [16]. Ex-
ecutive dysfunction has been associated with balance and gait difficulties 
in the healthy elderly [17] and the chances of developing dementia is 
three times higher in persons with gait disorders [18]. Additionally, PD 
patients suffering from gait and balance difficulties also perform poorly 
on spatial working memory tasks [19] and show increased gait difficulties 
during attention demanding dual-tasking [20]. Despite great progress in 
relieving many of the symptoms caused by dopamine degeneration, or 
abnormalities in dopamine transmission function, many executive dys-
functions as well as balance and gait difficulties remain hard to treat. 
Hence, the main aim of this thesis was to assess the function and mecha-
nism of an alternative or add-on therapeutic intervention in relieving 
hard to treat symptoms in dopamine related disorders.   
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Pathophysiology  
Parkinson’s disease 
Studies during the last few decades have illuminated the clinical features 
of this multisystem, multifactorial disorder. The age at disease onset can 
range between 31-85 years of age. Furthermore, a vast range of motor and 
non-motor symptoms have been identified [4, 8], some of which are 
levodopa responsive and others not [5]. Four subgroups of PD have been 
suggested: a young disease onset group, a rapid-disease progression 
group, a tremor-dominant group and a non-tremor-dominant group [21, 
22].  
Neuronal cell death occurs not only in the central nervous system but also 
in the peripheral nervous system [23]. Neurodegeneration starts before 
dopaminergic cell death in the SNpc, and spreads across and past differ-
ent areas of the basal ganglia circuitry. Indeed, Braak and colleagues [24, 
25] have argued that the pathological progression of the disease may 
originate from the lower brainstem, including the anterior olfactory nu-
cleus, medulla and pontine tegmentum. This supports the notion of a 
preclinical stage with non-motor indicators. They propose that dopamin-
ergic cell loss in the substantia nigra (SN) occurs somewhat mid-stage in 
the disease development, and thus correlates with the motor related man-
ifestations of the disease. Significant cognitive decline comes about at the 
latest stages when the cortical areas are affected, although mild cognitive 
impairment is often part of the early stage non-motor indicators. Sug-
gesting dopaminergic degeneration is only part of the etiology of PD, this 
hypothesis further acknowledges the role of other neurotransmitters in 
the development of PD symptoms. Altered serotonergic neurotransmis-
sion has for instance been connected to PD symptomatology [26]. Sero-
tonin receptors modulate the release and reuptake of dopamine as well as 
of GABA and glutamate. The dorsal and medial raphe nuclei are the main 
areas that send out serotonergic transmission to the striatum [27].  
Dopaminergic cell degeneration has been associated with both genetic 
and environmental factors [28]. What initiates neurodegeneration in the 
first place however remains largely unidentified. A marker for the disease 
that eventually leads to neuronal death and is associated with the degen-
erative process is the presence of Lewy bodies in the nerve cells [25]. The 
presynaptic nerve terminal protein α -synuclein, a key component in 
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Lewy bodies, is a contributor to PD pathogenesis, where dopaminergic 
neurons accumulate aggregates of misfolded α-synuclein [29].  α-
synuclein is not confined to the cell soma of involved cells in SNpc, but 
has been found in various brain structures in PD patients. In many cases 
it has also been found in other disorders such as Alzheimer’s disease (AD) 
and Multiple system atrophy (MSA) [23, 30].  
Recent research explains the role of autophagy on the development of 
mitochondrial dysfunction leading to increased Lewy-bodies [31]. The 
autophagy-lysosome pathway (ALP) is one of the most important mecha-
nisms behind recycling abnormal protein structures. During the process 
of autophagy, parts of the cytoplasm gets engulfed by a double-
membrane vesicle called an autophagosome, this in turn targets the lyso-
some in the cells and separates cytoplasmic compartments. This way, au-
tophagosomes repair or even eliminate protein aggregates on their 
transportation path from the tip of the axon toward the cell soma [32, 
33]. The overexpression of α-synuclein blocks autophagosome formation 
and inhibits the autophagy early in the process [31]. Thus, the aggrega-
tion of misfolded α-synuclein could cause disruption of the nervous sys-
tem’s normal ability to remove damaged proteins. Or vice versa, damaged 
protein accumulation which cannot get cleared out due to e.g. oxidative 
stress, may increase misfolded α-synuclein aggregates within the cell. 
Attention deficit hyperactivity disorder  
Known as a developmental neurobehavioural condition, generally ex-
pressed during preschool years, and often persisting into adulthood, 
ADHD is characterized by three dominant subtypes; hyperactive and im-
pulsive behaviour, inattentive behaviour or a combined type [34].  
Although the pathology of this disorder is unclear, the cortico-striato-
thalamical circuits, including the prefrontal brain regions as well as the 
basal ganglia, appear to be involved [35]. Some studies suggest that non-
fronto-striatal circuitries such as the cerebellum and the parietal lobes 
also play a role in ADHD manifestation [35]. A common pathophysiologi-
cal theory is that the brain dysfunction in ADHD is caused, at least in 
part, by abnormalities in the release and reuptake of the neurotransmit-
ters dopamine and noradrenaline. The theory is supported by the efficacy 
of psychostimulants, such as methylphenidate, that facilitate dopamine 
release in the treatment of ADHD [36].   
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It is possible that the different behavioural and neuropsychological char-
acteristics of ADHD have different genetic or environmental etiology 
[34]. Although ADHD symptomatology is often associated with higher 
dopamine reuptake, in what can be defined as a hypo-dopaminergic state, 
a hyper-dopamine state is also a possibility [11, 37]. A dual-pathway 
model has been suggested, with a diverse influence of cortical and sub-
cortical mechanisms in the different expression of ADHD [11]. Lower 
noradrenaline activity and its effect on dopamine transmission has been 
linked to a hyper-dopamine state and the interaction of dopamine and 
serotonin activity to a hypo-dopamine state [37].  
In a descriptive matched control study it was found that dopaminergic 
transmission in the brain’s reward pathway is less active in participants 
with ADHD [38]. Other researchers looked at the morphological charac-
teristics in several nuclei in the basal ganglia using magnetic resonance 
imaging (MRI) scans [39]. They found a decreased volume of the puta-
men in ADHD youths as compared with control youths. They further dis-
covered that the putamen, caudate and the globus pallidus (GP) were 
shaped differently in the ADHD youths, a finding that was not evident in 
ADHD youths treated with stimulants. Overall volume in the putamen 
was however not increased in the group treated with stimulants. There 
have been quite a few reports that the overall brain size of children and 
adolescents with ADHD is somewhat smaller than controls [40, 41]. The 
findings of a normalising effect of stimulants on brain size are however 
inconclusive, with some findings indicating a protective effect of stimu-
lants on brain size [42] and others indicating no effect of stimulants on 
brain size [41].  
The role of Basal Ganglia in movement and cognition  
Voluntary movement occurs when circuits within the brain receive and 
project signals to and from different brain structures and the premotor 
cortex and cerebellum. The basal ganglia, a group of nuclei situated in the 
midbrain and forebrain, consist principally of the striatum, GP, subtha-
lamic nucleus (STN), SN and the ventral tegmental area (VTA). The basal 
ganglia acts together with the cerebellum and spinal cord via the mid-
brain extrapyramidal area (MEA) and superior colliculus (SC) [43], as 
crucial subcortical structures that shape these signals before they reach 
their destination [44], Fig 1. Basal ganglia neurotransmission takes place 
primarily via two well-balanced pathways projecting from the striatum. 
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These are known as the direct and indirect pathways of the basal ganglia, 
where the striatum and the STN are the most prominent input nuclei and 
the SNr and globus pallidus internal segment (GPi) are the main output 
nuclei. The two pathways pose competing effects on movement and to 
some extent cognition. Facilitation in the basal ganglia nuclei with the 
inhibitory and excitatory function lead to the final selection of locomotor 
commands [45, 46].  
Basal ganglia circuits can also be seen as part of two main networks, the 
striato-nigral-striatal network and the thalamo-cortical-thalamic net-
work. Dopaminergic neurons receive direct and indirect input from the 
limbic system by means of the striatum. The mesolimbic dopaminergic 
pathways (responsible for the reward system as well as depressive and 
aggressive behaviour) and the nigrostriatal dopaminergic pathways (re-
sponsible for control of movement and motivated behaviours) are modu-
lated by the reciprocal striato-nigral-striatal network [47]. Within the 
thalamo-cortical-thalamic network on the other hand, one-directional 
pathways relay information to the cortex, including the prefrontal and 
supplementary motor areas. This network has a regulatory influence on 
automatic and voluntary motor execution and motor responses, reinforc-
ing wanted behaviour and suppressing unwanted motor and behaviour 
output [43], and has a similar function on attention and behavioural   
decision making [48].   
In the direct pathway, inhibitory (GABAergic) projection neurons in the 
striatum, known as medium-sized spiny neurons (MSNs), express dopa-
mine receptors D1 and project to the SNr and GPi nuclei. MSN neurons 
that project to the GPe nucleus are part of the direct loop and express D2 
receptors on their dendrites and cell bodies in the striatum [49]. Degen-
eration of dopamine terminals in the striatum leads to less activity in the 
D1-expressing MSNs of the direct pathway and increased activity of the 
D2-expressing MSNs of the indirect pathway. This results in an increased 
inactivity in the STN and an increased activity in the inhibitory output 
nuclei (SNr and GPi) which in turn impedes the selection and mainte-
nance of movements and probably also thought processes [50].  
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Figure 1 The normal circuitry of the basal ganglia. Located deep and central within the cerebral 
hemispheres, the basal ganglion connects to many areas of the brain. The main neurotransmitters 
are the inhibitory GABA (green), the excitatory Glutamate (GLU, red) as well as dopamine (DA, 
blue). Image adapted, original image by Patrick J. Lynch; 
https://creativecommons.org/licenses/by/2.5/legalcode 
 
 
Newer findings suggest that the dopaminergic system is more diverse 
than previously assumed. Dopamine axons from the SN have the ability 
to release GABA by activating the vesicular monoamine transporter for 
dopamine, VMAT2, and cause inhibitory responses in the striatum [51]. 
Similarly, GABAergic cells appear to have the ability to release dopamine. 
A cell population in the intact mouse striatum have been found to release 
GABA as well as contain Tyrosine Hydroxylase (TH), the rate limiting 
enzyme necessary for dopamine production [52, 53] suggesting there 
could be dopamine producing interneurons in the striatum itself.   
Subsets of dopamine neurons also have the ability to release glutamate 
through the vesicular glutamate transporter 2 (VGluT2). Glutamate re-
leasing dopamine neurons are mainly found in the VTA, but the VGluT2 
have also been found in the nucleus accumbens [54]. Stimulant drugs can 
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alter the locomotor response in knock-out mice lacking VGluT2 specifi-
cally in the dopamine neurons [55]. Thus, excitatory glutamate transmis-
sion from the VTA has a regulatory effect in physiological responses.      
Basal ganglia dysfunction plays a critical role in the development of many 
PD motor symptoms as well as non-motor symptoms. How exactly the 
loss of midbrain dopamine neurons cause alterations in the basal ganglia 
pathways leading to such a diverse disease profile is less understood. 
There are complex interactions between the different circuits, via the dif-
ferent neurons and neurotransmitters. The cerebellum also plays a part 
in these interactions as the cerebello-thalamo-cortical circuit has proven 
to be involved in PD tremors and motor behaviour [56]. To what extent it 
does so, is less clear.  
 
Non-invasive brain stimulation 
Invasive stimulation of targeted brain areas via implanted electrodes, 
deep brain stimulation (DBS), results in significant improvements of mo-
tor symptoms in PD. However, the mechanisms behind these effects are 
still not fully understood. An early theory, which may still partly hold 
true, suggests that local activation of the presynaptic inhibitory afferents 
inhibits the overactive neurons [57]. Newer findings suggest that DBS 
may improve PD symptomatology by modulating ongoing brain activity, 
through altering the electric activity known as brain oscillations [58, 59]. 
In recent years there has been a surge in the interest for non-invasive 
brain stimulation using direct or indirect non-invasive brain stimulation 
methods. In the direct stimulation methods the simulation is directed 
directly to superficial or deeper parts of the brain, whereas the indirect 
methods act by stimulation of peripheral afferents to the brain or spinal 
cord. The premise is that non-invasive stimulation methods could also 
have positive effects on motor and/or non-motor symptoms in neuro-
degenerative disorders such as PD, but without the need for an invasive 
surgical procedure. Dysfunctional neurotransmission can affect normal 
brain oscillations, and the theory is that by externally altering the brain 
oscillations, the neurotransmission could normalise to some degree. This 
in turn may have a positive effect on the behaviour affected by disease.  
Motor cortical excitability is commonly assessed by measuring motor 
evoked potentials (MEP). MEPs are muscle contractions as a result of the 
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neuro-electrical signals that arise from the spinal cord due to single or 
repetitive pulse-stimulation of the brain, thus give information of the mo-
tor cortex physiology during stimulation [60]. They do not necessarily 
provide evidence of any effect on motor behaviour.   
Direct methods 
Repetitive transcranial magnetic stimulation (rTMS) is administered via 
an electromagnetic coil on the scalp. The coil turns the electrical currents 
into magnetic fields which enter the brain surface without affecting skin 
or bone. The magnetic pulses which are directed repeatedly over the tar-
get area promote activity by inducing an electrical current between the 
nerve cells [61]. The effect of rTMS in PD is still subject to debate. On one 
hand some studies have found motor improvement in PD after rTMS, 
with gradual improvement of gait and hand bradykinesia over a 4 week 
period [62], and an immediate improvement of  cognitive processing on 
the Stroop test after rTMS [63]. On the other hand recent studies have 
shown that gait, bradykinesia, rigidity, tremor, axial symptoms and the 
Unified Parkinson's Disease Rating Scale (UPDRS) scores are not affected 
by rTMS after short but consecutive use, regardless of low (1 Hz) frequen-
cy [64] or high (50 Hz) frequencies [65]. 
Transcranial direct current stimulation (tDCS) is delivered through skin 
electrodes placed on the scalp over cortical target areas and directly stim-
ulate or inhibit (depending on the polarity of the electrode) the underly-
ing neuronal tissue. In a recent study, stimulation of the primary motor 
cortex in PD patients resulted in improvement in both number of and the 
duration of freezing of gait events [66]. In another study, tDCS through 
the motor and prefrontal cortices was evaluated to establish any effect on 
gait and bradykinesia as well as several other PD symptoms. The primary 
outcome was a slight improvement of gait, with increased walking speed 
off-medication, however this effect only lasted for a short while and did 
not occur while on medication [67]. When analysing cognition during a 
working memory task in a PD cohort off medication, tDCS delivered to 
the left dorsolateral prefrontal cortex was found to improve performance 
[68]. 
Transcranial alternating current stimulation (tACS) is applied by at-
taching two or more electrodes on the scalp. The alternating sinusoidal 
current is believed to synchronise neuronal networks, like an external 
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electrical oscillation that is interacting with ongoing oscillations in the 
cortex. Thereby it could retune unusual oscillatory patterns associated 
with PD symptomatology [69]. Resting tremor in PD could be reduced by 
almost 50% with tACS over the motor cortex [70]. Additionally, sinusoi-
dal tACS at 20 Hz over the motor cortex has been found to slow down 
voluntary movement during a visuomotor task in healthy participants 
[71]. This suggests an inhibitory effect, which could alter underlying mo-
tor control by adjusting neuronal communication. EEG assessments of 
tACS oscillatory effects suggest that alpha band oscillations are elevated 
even after stimulation [72, 73].  
Transcranial random noise stimulation (tRNS) is administered by    
placing a stimulation electrode over the target area and a reference elec-
trode on the contralateral side. In a healthy participant group, tRNS over 
the motor cortex enhanced corticospinal excitability. This occurred spe-
cially during the higher frequency spectrum, and appeared to last for 60 
min after the 10 min stimulation period [74].  The mechanism of how this 
excitability comes about is unclear. It is believed that tRNS interferes 
with the ongoing neural oscillations and thereby modulates cortical excit-
ability. Carbamazepine (CBZ), a voltage-gated sodium channel blocker, 
has been found to significantly shorten the excitability effect of tRNS, 
suggesting that the application of repetitive tRNS may alter the repolari-
sation and depolarisation of the ion channels and thereby increase corti-
cal excitability [75]. This is possible as CBZ has a cell membrane 
stabilising quality and has an effect only when the membrane potential is 
reduced. With repetitive high-frequency stimulation, which activates the 
sodium channels and increases depolarisation, CBZ binds to the sodium 
channels and slows down the depolarisation process [76]. When this pro-
cess is repeated continuously, the sodium channels constantly repolarise 
and depolarise, thereby yielding a heightened effect of tRNS and           
increased excitability [74]. It could be argued that this repetitive effect 
increases neuro-plasticity and leads to enhanced cognitive performance. 
Indirect methods  
Vagus nerve stimulation (VNS) is designed to send regular, mild electri-
cal pulses to the brain via the vagus nerve, a major component of the au-
tonomic nervous system. The vagus nerve is part of the peripheral 
nervous system and makes its way from the medulla in the brainstem and 
directly out to the body. It appears that about 20% of the fibres in the  
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vagus nerve carry information from the brain to the body (efferent), while 
the rest of the fibres carry information from the body to the brain         
(afferent) [77]. Furthermore, it regulates cognitive functions through  
direct and indirect connections to the cortical-limbic-thalamic-striatal 
neural pathways [78]. VNS is currently used in epilepsy but could be an 
emerging technology for treating other neurological disorders too. In a 
study looking at skilled motor tasks in rats, VNS during 5 days of training 
was found to increase the area of the motor cortex [79], suggesting VNS 
could have an effect on plasticity within the motor system. In a clinical 
word recognition task, participants read a section with some highlighted 
words, after which they either underwent VNS or not [80]. The subjects’ 
ability to remember highlighted words improved significantly after VNS. 
Therefore, it is possible that VNS may have the ability to enhance 
memory retention.      
Transcutaneous electrical nerve stimulation (TENS) is applied via either 
one set or two sets of electrodes directly on the skin, emitting low-voltage 
electrical currents. These currents can be adjusted for pulse, frequency 
and intensity, classified as high frequency (>50 Hz), low frequency (˂10 
Hz) or in burst configuration where bursts of a high frequency is submit-
ted intermittently during a low constant frequency [81] . It is widely used 
for treating acute and chronic pain, often following neurological disorders 
including musculoskeletal diseases and neuropathy [82]. In PD it is 
sometimes used as complimentary therapeutic aid in aim to reduce pain 
following muscle tension and rigidity, although very few clinical studies 
have been conducted to assess its benefits in PD. Some studies have 
looked at the effect of TENS on motor impairment. In patients with dys-
tonia,  TENS was found to improve handwriting [83] and it improved the 
abdominal dyskinesia dramatically in a case study [84].  
Step-synchronised vibration therapy has been assessed for treating gait 
disturbances in PD. Short-term effects of this procedure appear to im-
prove gait steadiness [85]. The method involves small vibration devices 
embedded at different pressure points in the soles of constructed shoes. 
These deliver supra-threshold (70 Hz) vibration pulses when pressed 
down during walking which stop when pressure is eased [85]. In a recent 
study the effects of this procedure was assessed during 1 week in a partic-
ipant with freezing of gait difficulties and in a participant with implanted 
DBS. In both PD cases there was improvement in several gait indices 
[86].  
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Acoustic sensory noise is a non-invasive method which could indirectly 
stimulate different neurological pathways. This method entails adding 
high level (65-85 dB) white background noise. The noise is delivered bin-
aurally using high quality headphones with a stochastic (randomly fluc-
tuating) frequency during testing. Auditory processing allows the acoustic 
noise carrying waves to reach the auditory pathways, where they are 
turned into neuronal action potentials through transduction. After this, 
the sound stimuli is encoded and transmitted to subcortical structures for 
specific processing [87]. Therefore, higher cognitive function could indi-
rectly be affected by acoustic noise. The effects of this kind of stimulation 
have been assessed mainly on cognitive function. Acoustic noise appears 
to improve cognitive performance in low-attentive children, while having 
the opposite effect in super-attentive children and has no significant ef-
fect in normal-attentive children [88], potentially counterbalancing epi-
sodic memory differences between low-attentive and normal-attentive 
children [89], irrespective of medication [90]. Acoustic stochastic noise 
also appears to prompt positive effects, similar to stimulants, on motor 
learning in the spontaneously hypertensive (SH) rat model of ADHD but 
not on control rats [91].  
 
Stochastic Vestibular Stimulation 
The vestibular system  
Within the vestibular system, Fig 2, the sensory organ in the inner ear 
contains three semi-circular ducts (anterior, horizontal, posterior) bilat-
erally, which respond to rotational movements and head acceleration. 
The utricle and saccule, the two otolith organs connecting to the ducts, 
react to linear accelerations. A head movement or acceleration in one di-
rection excites the receptor cells in the semi-circular ducts on one side 
while inhibiting them on the other side, as fluid moves the vestibular hair 
cells in opposing directions [92]. There is a constant discharge of vestibu-
lar afferent neurons and the vestibular system responds to very small 
head movements and changes in gravity (which is a form of linear accel-
eration). The vestibular system reflectively regulates muscular as well as 
autonomic responses to the body’s spatial orientation, thereby maintain-
ing postural balance and providing early cardiovascular responses to 
changes in gravitational direction when a person stands up e.g. One of the 
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best studied vestibular reflexes is the vestibulo-ocular reflex (VOR) which 
stabilizes gaze. The vestibular system also provides crucial information to 
the hippocampus which enables the spatial specificity of hippocampal 
place cells and thereby plays an important role in spatial orientation in-
cluding the maintenance of an internal map of our environment [93-95].  
   
 
 
 
Figure 2 Vestibular system, the vestibular nerve connects to the semi-circular ducts and 
the auditory nerve connects to the cochlea in the inner ear.  View from behind, parallel to 
the posterior part of the petrous bone right under the mastoid process, marked red on the 
skull image.  
Image adapted, original images by Patrick J. Lynch and Database Center for Life Science 
https://creativecommons.org/licenses/by/2.5/legalcode 
 
 
The inferior, medial, lateral and superior vestibular nuclei are located in 
the medulla and pons found in the brain stem, connecting to the mesen-
cephalon. Projections from the peripheral end organs go through the ves-
tibular afferent nerves in the internal auditory meatus to one of the four 
vestibular nuclei and onwards from there to cerebellum, cortex, and other 
brain structures.    
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The gaze stabilizing VOR generates an eye movement in response to a 
head movement, and allows the gaze to stay fixed in relation to the sur-
rounding. The central vestibular system can distinguish tilts of the head 
and VOR takes place despite angular or linear head accelerations [96]. 
The vestibular afferents also evoke head-stabilisation in space during lo-
comotion, the vestibulo-collic reflex (VCR). Sensory processing in the 
brain stem initiates the VCR. Vestibular neurons receive convergent input 
from the cerebellum as well as the semi-circular ducts and the otolith or-
gans, these further descend to the spinal motor neurons [97]. Head rota-
tion in a different direction than the body’s direction is driven by this 
reflex as well [98].  
If vestibular afferent signals are less than optimal, the appropriate bal-
ance response may be impaired. In PD, the loss of optimal dopaminergic 
regulation in the basal ganglia also produces difficulty in patients adapta-
tion to postural disturbances [99]. Researchers have demonstrated im-
paired balance control in healthy participants after they received 
erroneous vestibular afferent signals [100]. Visual input and somatosen-
sory inputs are also of importance for optimal balance control. One way 
to assess the part these factors play for postural control is by the Rom-
berg test. By standing with feet close together and arms crossed over the 
chest, one can appreciate the difference in maintained balance with eyes 
open or eyes closed. For a more demanding version, this can be done on a 
compliant surface like a mattress. In PD, balance control is significantly 
reduced during this test compared to age matched controls [101, 102].   
Basal ganglia receive vestibular information via a number of different 
pathways through various regions including the motor cortex and the 
hippocampus. Most recent studies of the vestibular-basal ganglia connec-
tion suggest that vestibular signals go through the dorsolateral striatum 
as a main input site and thereby modulate motor behaviour [92]. A recent 
finding in mice [103] was that both dopaminergic and GABAergic neu-
rons in the SN are necessary for postural control and are specifically acti-
vated by head tilts. Both kinds of neurons receive input from the 
vestibular system mediated via the subthalamic nucleus (STN) and the 
pedunculopontine nucleus (PPN) [103].  
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Why SVS?  
Transcutaneous galvanic stochastic vestibular stimulation (SVS) is an 
adaptation of galvanic vestibular stimulation (GVS), with the element of a 
noisy signal. It is therefore sometimes referred to as noisy GVS. Both pro-
cedures involve applying a cathodal current (negative) on one side and an 
anodal current (positive) on the opposite side [104, 105]. The difference 
between the two procedures lies in the applied waveforms. While studies 
with GVS employ structured square-waved, sinusoidal direct currents, 
the stochastic application employs a randomly fluctuating (usually im-
perceptible) current. When this current is applied at a near threshold 
amplitude, it is possible to affect vestibular afferents without unpleasant 
side-effects such as skin-irritation, nausea, vertigo or nystagmus [106]. In 
fact, it appears that near threshold currents particularly activates afferent 
neurons with irregular spontaneous firing rate [107] and could therefore 
target only certain vestibular afferents. By exciting the receptor cells, a 
response is initiated without engaging other sensory systems [105]. It has 
been hypothesised that the otolith, and not the semi-circular ducts, main-
ly responds to near threshold galvanic vestibular stimulation of the ves-
tibular nerve [108]. In SVS, the amplitudes are usually set individually as 
different amplitudes are required to produce the same effect in different 
individuals. The sensory threshold here refers to the amplitude where an 
ordered (e.g. sinusoid or square wave) current leads to a noticeable acti-
vation of the vestibular system in the individual, with a gentle rocking of 
the head, or a sensation that the head is rocking. The frequency in most 
studies using stochastic currents is between 0-30 Hz, although in some 
studies frequencies can range up to 50 Hz or even higher.    
In two clinical studies on healthy participants, low-intensity SVS was 
found to have the greatest effect in improving walking stability and bal-
ance performance in the range of 0.1-0.5 mA (amplitudes tested were 
between 0-1.5 mA) [109, 110]. Walking stability was assessed during a 
perturbed walking condition with a treadmill that moved from side to 
side [109]. The effect of SVS on balance performance was measured dur-
ing a version of the Romberg balance task where participants stood on 
medium density foam [110]. Another study on healthy participants found 
that SVS evokes muscle responses in the lower limbs during regular 
stance, at a high intensity (±3 mA, 0-20 Hz) applied in a binaural bipolar 
arrangement. These effects were not found during other electrode place-
ments (like the forehead), suggesting lower limb muscle responses as a 
specific consequence of modulated firing of the vestibular afferents [111].      
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The motor responsiveness, as measured by trunk activity, and heart rate 
dynamics of patients with PD or multisystem atrophy, was improved dur-
ing the application of SVS (mean current = 0.33 mA) [112]. Improvement 
of trunk activity was also found in PD patients unresponsive to levodopa 
medication. The authors suggest that noisy vestibular stimulation can 
improve the function of the neurodegenerative brain in these disorders. 
Furthermore, balance function has also been assessed during noisy ves-
tibular stimulation. A small decrease in sway was found in PD patients 
but not in healthy controls during low 0.1 mA intensity [113]. A recent 
study has found that SVS improves motor performance in a visuomotor 
tracking task [114], thus signifying that SVS may induce an effect also on 
sensorimotor processing.  
As well as improved motor function, low-intensity SVS have been shown 
to improve cognitive performance in PD. An improvement of reaction 
time during cognitive assessments in the levodopa unresponsive PD pa-
tients has been demonstrated, suggestive of increased autonomic respon-
siveness [112]. Although studies on the role of SVS in cognitive 
performance are limited, the effects of GVS have been studied to some 
extent, suggesting a link between vestibular information processing and 
cognitive performance. Low-intensity GVS (0.7 mA) in hemi-spatial ne-
glect was found to reduce deficits in a number of object-centred visuospa-
tial tasks, including the line bisection task [115]. GVS in this configuration 
have also been found to improve a figure copying deficit in a case study of 
hemi-spatial neglect [116]. Furthermore, a large study found long lasting 
positive effects of GVS on the Behavioural inattention test (lasting for at 
least 1 month) [117]. Interestingly, GVS has been found to have an en-
hancing effect on the line bisection task in visuospatial neglect, but not in 
stroke patients without neglect [118]. Thus, it appears that vestibular 
stimulation may enhance neuronal interaction in patients with stroke, 
where spatial cognition is impaired, affecting bilateral integration. In 
view of that, supra-threshold GVS (2 mA) also improved postural asym-
metry significantly in patients with left or right hemispheric lesion [119].  
SVS – what actually happens?  
While visual and proprioceptive information help to maintain the postur-
al control system, vestibular information is critical for sustaining balance 
[104]. In disorders where balance is impaired, vestibular stimulation   
appears to increase the attentiveness to vestibular cues, instigating an 
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effect on motor problems [120, 121]. How sustainable this effect is in do-
pamine related disorders is still largely unknown.  
One theory is that the stochastic sensory stimulation can improve the 
performance of neuronal systems by a phenomenon known as stochastic 
resonance (SR). This entails that near threshold noise can help carry a 
weak signal through a non-linear system to the detection threshold [122, 
123]. SR can thereby affect physiological systems within the individual, in 
many instances improving less-than optimal function [124]. The moder-
ate brain arousal (MBA) hypothesis introduced in 2007 [125] proposes 
that adding a moderate level of white noise to a low noise system will im-
prove neuronal system function, but only if the neuronal system is not 
working optimally already (which is a general condition for SR). The 
MBA theory also assumes that low levels of dopamine transmission may 
be associated with insufficient neuronal noise, which in turn impairs the 
neuronal communication. Adding external noise would improve the func-
tion of neuronal systems in hypodopaminergic conditions, but would 
have no positive effects in an optimally working system with normal do-
pamine transmission [125, 126].  
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AIMS 
Overall aim of thesis 
The overall aim of this thesis was to assess the effects of galvanic SVS in 
relation to levodopa in both clinical and preclinical trials, and to evaluate 
the possible mechanisms behind these effects. Furthermore, we were in-
terested in whether SVS has the same positive effect on cognitive perfor-
mance in ADHD as auditory stochastic noise appears to have.   
Specific objectives 
1. How does SVS affect brain activity in the intact and the dopamine 
hemi-lesioned brain?  
 
2. What are the similarities of SVS and levodopa in terms of brain 
activation patterns and neurotransmission? 
 
3. Does SVS improve motor performance in an animal model of PD? 
 
4. Is SVS tolerated in combination with levodopa in PD patients? 
 
5. How do behavioural SVS effects compare with levodopa effects in 
patients with PD? 
 
6. Does SVS induce similar improvements in cognitive performance 
in ADHD as acoustic noise? 
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MATERIAL & METHOD  
The first three studies carried out for this thesis primarily assessed the 
effects of galvanic stochastic vestibular stimulation (SVS) on motor per-
formance and the underlying brain activity which could explain these 
possible effects. The first two studies used the 6-hydroxydopamine hy-
drochloride (6-OHDA) hemilesioned rat model of PD. The third study 
assessed the effects of SVS and levodopa in a clinical cohort of partici-
pants with PD. Finally, the possible effect of stochastic vestibular stimula-
tion on cognitive performance was trialled in a clinical cohort of subjects 
with attention deficit hyperactivity disorder (ADHD).   
 
SVS protocol  
Three different setups were used for the stimulation protocol during the 
four different studies. During the first preclinical study (paper I) the Neu-
roLog NL800 (Digitimer Ltd. Hertfordshire) and the analogue stimulus 
isolator 2200 A-M Systems (Sequim, Washington, USA) were used to 
apply sinusoidal and stochastic noise. For study III, the first clinical pilot 
study, a portable and programmable stimulation device [127] developed 
at Universities Space Research Association, Houston Tx, USA, was used. 
In paper II and IV a new portable device (Galvanic Stimulator, Ilves engi-
neering, Gothenburg, Sweden) was used, specifically designed and devel-
oped for in house trials with galvanic stimulation, Fig 3.  
The stimulator was programmed to deliver a sinusoid signal (1 Hz) at dif-
ferent amplitude levels, which was used to determine the individual 
threshold for stimulation induced perceptible sway. The lowest amplitude 
level where a gentle rocking of the head (from side to side) became no-
ticeable was used as the maximum allowed amplitude of the SVS proto-
col. As a second step, the stimulator was reprogrammed to deliver bipolar 
stochastic vestibular signals, using a Gaussian white noise pattern gener-
ator filtered using a 10th order low-pass Butterworth filter with a cut-off 
frequency at 30 Hz.  
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Figure 3 Programmable Galvanic stimulator in study II and IV. In study II, the electrode 
wires were connected to small crimp contact electrodes placed on the top of the rat skull. 
In study IV electrodes (as seen on image) were firmly placed over the mastoid process.  
 
 
Preclinical studies (paper I & II)  
Animals  
The local ethical committee Göteborgs djurförsöksetiska nämnd and UK 
Home Office approved all surgical and experimental designs, in accord-
ance with the European Communities Council Directive of November 
24th, 1986.  
Sprague Dawley (SD) rats were used for the experiments. In paper I, fe-
male rats were used due to their smaller weight gain over time as weight 
gain may distort the results in the motor performance tests. The normal 
unlesioned rats in the microdialysis trial were male, as they did not un-
dergo behavioural testing. In Paper II, male rats were selected to avoid 
interference of the female cycle on brain activity, as the behavioural test 
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element was redundant. Animals were maintained in a conventional ani-
mal facility with a 12 h light/12 h dark cycle, in cages of four, with access 
to food and water. Before any behavioural training or test, animals were 
given the opportunity to acclimatise to new surroundings. 
Surgical procedures  
6-OHDA lesions are extensively studied in rat models of PD, where the 
neurotoxin is injected in distinct brain structures, promoting dopaminer-
gic cell death. In our model, we injected this toxin hemi-laterally in the 
medial forebrain bundle, causing destruction of the nigro-striatal path-
way.   
The lesion procedure was performed under isoflurane anaesthesia. The 
skull was exposed, a hole was drilled over the medial forebrain bundle 
and 6-OHDA dissolved in 0.9% NaCl, 0.3% ascorbate, 5 µg/µl, was in-
jected. The hole was covered with periost membrane and the wound was 
closed. Sham-treated animals received the saline ascorbate vehicle only. 
Approximately 4-6 weeks after the lesion procedure, sterilised vestibular 
electrodes were implanted in a bilateral arrangement. The electrodes 
were constructed in our labs, using Teflon coated stainless steel wires 
(0.2 mm Ø) and small crimp contact electrodes. The animal was put un-
der anaesthesia as described, the skull was exposed and two stainless 
steel jeweller’s screws were fastened in the parietal bones, the electrodes 
were lowered gently and fastened with acrylic cement foundation. The 
surgical area over the horizontal canals of the two labyrinths was then 
exposed and the 1 mm peeled, and looped, end of the steel wire was se-
cured by pushing it through the most ventral ends of the bilateral petrosal 
crests, Fig 4. The wounds were closed with the electrodes externalised. 
Some animals received microdialysis implants (paper I) in the same    
surgical session.  
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Figure 4   Illustration of the electrode placements. Two crimp contact electrodes were fastened on the 
top of the parietal bones with acrylic cement. Bilaterally, the petrous part of the temporal bone was 
identified and the peeled 1mm end of a 0.2mm Ø steel wire was secured through the most ventral end 
of the crest. Wounds were closed over the wires by stitching, and the electrodes were left externalised. 
 
 
Microdialysis (paper I) 
Microdialysis is a method used to sample and measure neurotransmitters 
and other soluble molecules in the extracellular tissue fluid [128]. We 
employed this technique to analyse different monoamines and their me-
tabolites in selected brain areas affected by PD and directly related to the 
basal ganglia pathways or involved in brain stem afferent processing. 
The microdialysis probe locations were determined with reference to the 
Paxinos and Watson rat brain atlas [129] and were implanted bilaterally 
in the striatum, substantia nigra (SN), pedunculopontine nucleus (PPN) 
and ventromedial thalamus (VM). Samples were collected every 30 
minutes, after two baseline samples, stochastic vestibular stimula-
tion/sham stimulation was conducted for 30 minutes. Microdialysis per-
fusion continued for another 60 minutes, providing totally 5 
microdialysis samples from each probe. The following day the same ani-
mals received a single injection of levodopa and benserazide (6 mg/kg 
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and 12 mg/kg, respectively, i.p.) or saline instead of stochastic stimula-
tion.  
The collected samples were analysed for basal levels of amino acids and 
neurotransmitters, including dopamine, serotonin (5-HT), GABA and 
glutamate concentrations. The dialysate fractions were analysed for 
amines and amine metabolites by using a two-dimensional high perfor-
mance liquid chromatography system with electrochemical detection 
(HPLC-ED), and amino acids were separated and detected by HPLC fol-
lowed by fluorescence detection after pre-derivatization with                      
o-phthaldialdehyde (OPA). 
Immunohistochemistry (paper II)  
c-Fos protein expression (the protein product of the immediate early 
gene c-fos mRNA) can be used to demonstrate neuronal activity in a sub-
set of cells and can be viewed as markers that visualise neuronal interac-
tion in functional pathways [130].    
After recovering from the vestibular electrode implantation (3-5 days), 
the animals received either SVS or sham SVS for 30 minutes and under-
went a transcardial perfusion 90 minutes after stimulation seized. Alter-
natively, they were perfused 120 minutes after a levodopa and 
benserazide (6 mg/kg and 12 mg/kg, respectively, i.p.) or saline injection.  
Immediately after perfusion, the brain was removed and post-fixed in 
paraformaldehyde (4%, ph 7.4). The brain was sliced in serial coronal 
sections (35 µm) using a cryostat and went through a series of incubation 
procedures. As a final step they were stained with peroxidase DAB solu-
tion (25 mg/mL 3,3′-diaminobenzidine and 0.005% H2O2) to achieve a 
colour reaction which was analysed to assess expression of the c-Fos pro-
tein  in different brain regions.  
Assessments  
For the behavioural assessments (paper I) we trained the animals for two 
tests, the Rotarod locomotion test and the Montoya staircase test, Fig 5. 
 
 
 
 
MATERIAL & METHOD  
35 
 
 
 
Figure 5 The Rotarod locomotion test and the Montoya staircase test. A) Accelerating 4-lane Rotarod 
for rats. When the rat stops running, it will glide down to the lever which will record the time. B) The 
Montoya staircase box. Sugar pellets are placed in little wells on each stair and the rat will have to reach 
out with the forelimb to retrieve them.  
Images A with permission from https://creativecommons.org/licenses/by-sa/4.0/deed.sv 
Image B has been reprinted with kind permission from C/O Lafayette Instrument Company, Inc. 
 
 
Rotarod has previously been demonstrated as a highly sensitive measure 
for motor impairment after brain injury [131]. We tested the animals on 
the Rotarod in order to assess motor behaviour during the different con-
ditions. Animals were trained on the accelerating rod before any surgical 
procedures took place. Three weeks after the lesion procedure, the ani-
mals were tested, to assess the time spend on the rod. Testing was further 
conducted three to five days after electrode implantation. Treatment or 
sham treatment was administered in a counterbalanced order, with ani-
mals receiving either treatment or sham treatment on one day and the 
opposite condition on the following day. The animals were stimulat-
ed/sham stimulated for 30 min prior and throughout the testing period. 
Alternatively levodopa or saline was injected 30 min prior to testing.  
To measure fine motor skills we further tested the animals in the Mon-
toya staircase test, an objective test of skilled reach and independent use 
of forelimbs [132]. Before the lesion procedure, rats were food restrained 
and trained to retrieve sugar pellets, having to reach out their forelimbs 
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from a small plexiglas box with a staircase on each side. One week after 
electrode implantation, the rats were food restrained once more and test-
ed in a counterbalanced order. Due to technical reasons, the animals were 
stimulated for 30 minutes prior to the testing only.  
For paper II, we first screened all brain sections visually to assess any 
emerging c-Fos expression and identify possible group-specific patterns 
in regions based on Paxinos and Watson rat brain atlas [129]. At the ini-
tial screening the examiner was blinded to groups and treatments. The 
regions which appeared to have group specific c-Fos expression were the 
dorsal peduncular (DP), nucleus accumbens (Acb), lateral habenula nu-
cleus (LHb), reticular thalamic nucleus (Rt), intermediate nucleus of lat-
eral lemniscus (ILL), brachium inferior colliculus (BIC) and the 
cuneiform nucleus (CnF). Beside this unbiased selection of brain regions, 
we had some predetermined regions of interest based on previous re-
search that we also chose to assess further. This selection included the 
substantia nigra (SN), pedunculopontine nucleus (PPN), ventromedial 
thalamus (VM), caudoputamen (CPu), subthalamic nucleus (STN) and 
the vestibular nuclei including the medial vestibular nucleus (MVePC) 
and the ventrolateral medullary region (RVLM). Full cell quantification 
was performed using ImageJ (U.S. National Institutes of Health, Bethes-
da, Maryland, USA).  
 
Clinical studies (paper III & IV) 
Participants  
Approval of the clinical studies was obtained from the regional ethical 
review board in Gothenburg, and written informed consent was obtained 
before any testing commenced. Participants were encouraged to report 
any discomfort throughout the entire trial, and any adverse reactions 
were noted. At the end of the entire trial, participants were debriefed us-
ing a structured interview protocol. 
Paper III was a pilot study with the main aim to investigate the feasibility 
of use of an SVS device in PD. Thus our sample, recruited from the Neu-
rology Clinic at Sahlgrenska University Hospital in Gothenburg, Sweden, 
was quite small (n=10). The study followed a randomised crossover de-
sign, which took place during two different days, generally one-two weeks 
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apart. The effects of SVS or sham SVS were evaluated after 12 h of medi-
cation abstinence as well as after a single dose of levodopa, Madopar 
Quick, 200 mg. The stimulation procedure was double-blinded, due to 
obvious reasons the medication was not. As the effect of medication was 
of importance in the study, responsiveness to levodopa was part of the 
inclusion criteria, as was a Hoehn & Yahr disease stage of ≤3. Excluded 
were participants with implanted electronic devices or diagnosed vestibu-
lar diseases.     
The final study in this thesis (paper IV) was carried out in collaboration 
with the Gillberg Neuropsychiatry Centre in Gothenburg, Sweden and the 
Child and Adolescent Psychiatric unit, Lund, Sweden.  
 
 
 
Table 1 
Baseline characteristics of study participants in Paper IV, ADHD-I = Inattentive type, ADHD-H = Hyper-
active-Impulsive type, ADHD-C= Combined type, ADD = Attention Deficit Disorder.  
Subject  Age Sex Medication Subtype  mA 
1 8 M None ADHD-I 300 
2 10 M None ADHD-C 300 
3 11 F None ADHD-C 300 
4 12 M Concerta ADHD-C 450 
5 13 F None ADHD-C 450 
6 14 M None ADHD-C 400 
7 14 M Concerta ADHD-C 600 
8 14 M Concerta  ADHD-C 600 
9 17 M None ADHD-I 300 
10 18 M None ADHD-I 400 
11 19 F None ADHD-I 300 
12 20 M None  ADHD-I 400 
13 22 M None ADHD-C 450 
14 23 M None ADHD-I 400 
15 37 M Ritalin ADD 350 
16 42 M None Data missing 600 
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Included in the study were participants (n=16, Table 1) with definitive 
ADHD diagnosis, irrespective of subtype at this stage, as this pilot study 
aimed to investigate the effects of SVS on cognitive ability in typical 
ADHD.  The exclusion criteria were implanted electronic devices, comor-
bid autism, epilepsy or Tourette’s syndrome. Similar to the study in paper 
II a double-blinded crossover design was followed. All participants func-
tioned as their own control and underwent testing with SVS and sham 
SVS in different trials with at least one week interval to minimise any car-
ry-over effects. Evaluations were conducted after a minimum 12h wash-
out of any ADHD medication. 
Behavioural assessments 
Dynamic balance response test (paper III): The participant wore a har-
ness, connected to a thin rope which pulled with a force corresponding to 
3% of the participant’s weight, creating a slight and steady pull. Suddenly 
releasing the rope with an electromagnetic switch, a spontaneous back-
ward sway was produced until the subject reacted, stopped and reversed 
the backward sway. Sway movements in anterioposterior (Y) and medi-
olateral (X) directions, as well as the perturbation correction time(s) were 
recorded using a Kistler force plate (Kistler Nordic AB, Sweden).  
 
Static balance tests (paper III): The participant stood on the force plate, 
barefoot, eyes closed and arms folded over chest. The same procedure 
was conducted while the participant stood on a 10 x 5 x 50 cm pad of me-
dium density foam, decreasing the proprioceptive input.  
 
Unified Parkinson's disease rating scale, UPDRS (paper III): A trained 
examiner performed UPDRS part III, while recording the examination 
with a full HD camcorder. The evaluation was done twice by the same 
rater, once immediately after session and once on a later occasion. When 
ratings differed between the two assessments a second trained rater was 
consulted for arbitration. 
Posturo-Locomotor-Manual test, PLM (paper III): An optoelectronic 
measuring system (Qbtech/PDMonitor, Qbtech AB, Sweden), recorded a 
repeated movement where the participant picked up an object and trans-
ferred it to a chin-levelled platform 2 m ahead.  
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The Rey Auditory Verbal Learning Test, RAVLT (paper IV): This word-
recall test evaluated short-term verbal memory. Participants listened to a 
list of 15 unrelated words and were asked to repeat the words they re-
membered, in five repeated trials. This was followed by a distractor list 
with 15 other unrelated words which subjects were asked to repeat. Final-
ly they were asked to retrieve as many words as they remembered from 
the initial list. 
Span-board task (paper IV): To assess visuo-spatial working memory, 
participants were sat in front of a screen where stimulus sequences were 
presented, starting with a short sequence which became longer and more 
difficult with each trial. Participants were asked to repeat each sequence 
on the screen immediately after it was shown. The test continued until 
the participant made an error two sequences in a row.  
Flower trail test (paper IV): A trailing/tracking test was used to evaluate 
visually aided learning of a new motor skill. Participants drew a line be-
tween two lines shaping a large flower pattern, without lifting the pen and 
while avoiding to transect the lines. The completion of each identical 
flower pattern was timed, and 15 patterns were completed.  
 
Statistical analysis 
All statistical analyses were performed using SPSS (PASW Statistics 18), 
and the significance threshold was set at 0.05. 
Paper I 
Repeated measure two-way ANOVA was used to evaluate the treatment 
effect on neurotransmitter concentrations, with treatment and time as 
independent factors. Subsequently, one-sample t-tests were conducted 
where appropriate. Paired t-tests evaluated effects of SVS on change in 
locomotion time (s) on rod. In the Montoya skilled reach test, the overall 
number of sugar pellets consumed, total number of pellets on each side as 
well as the ratio between number of pellets eaten from impaired (con-
tralesional) side and non-impaired (ipsilesional) side after SVS or sham 
SVS were evaluated by paired t-tests.  
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Paper II 
Each investigated region was analysed separately with a fixed-effect, un-
structured linear mixed model to analyse c-Fos protein positive cell 
count. Ipsi- and contralesional side was used as repeated measures, and 
the treatment (SVS/levodopa/saline) and condition (6-OHDA hemi-
lesion/sham hemilesion) was used as independent factors. 
Paper III 
Data distributions were normalised with logarithmic transformations and 
all data except maximum sway passed normal distribution tests. Non-
parametric Friedman test, with Wilcoxon’s paired test as a post-hoc 
measure was used to analyse maximum sway. Other variables were ana-
lysed with repeated measures linear mixed model analyses (fixed-effect, 
unstructured) to assess the main effects of SVS and levodopa treatment 
as well as interaction between the two. In the static posturography, re-
duced proprioceptive input was used as a third main factor. 
Paper IV 
The different variables from span-board test were analysed using linear 
mixed model analysis (fixed-effects, unstructured), with trial day and tri-
al number as repeated measures and treatment (SVS/sham SVS) as a fac-
tor. For the Rey AVLT, repeated measures two-way ANOVA was 
performed, assessing the mean difference of the first trial to trial 2-5, as 
well as the treatment effect on trial 1-5. Treatment effect on the final re-
call trial was computed with a paired t-test. For the Flower trail test, two-
way ANOVAs were carried out for drawing time and number of errors, 
with the treatment group as a factor. A Pearson product-moment correla-
tion coefficient was computed to assess the relationship between the dif-
ferent parameters.  
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RESULTS & DISCUSSION 
Based on previous research, we assumed stimulation of the vestibular 
pathways could have some potential as a therapeutic aid in dopamine 
related disorders. The physiological effects of SVS on brain function, spe-
cifically in comparison to levodopa have not been elucidated. Just as im-
portantly, there is a lack of knowledge about the clinical effects of SVS on 
motor function in PD and cognitive performance in ADHD, with or with-
out the combination of specific medication. This thesis was aimed at in-
vestigating some of these aspects, and to add clues to how SVS may affect 
symptoms mainly in PD, but also in ADHD. 
 
What are the mechanisms of SVS? 
To assess how the activity pattern and neurotransmission in the brain 
may change during SVS, microdialysis was carried out in rats in four key 
brain regions connected to the basal ganglia circuitry. Extracellular con-
centrations of dopamine, dopamine metabolites and amino acids were 
collected from the striatum, SN, PPN and VM before, during and after 
SVS and levodopa treatment.  
In unlesioned animals GABA concentrations increased in the SN after 
SVS, while remaining unchanged after sham SVS. The results suggested 
that the increase started early in the SVS procedure and remained for at 
least 30 min after stimulation ceased. Dopamine levels remained un-
changed in the SN and the striatum. SVS also affected the glycine and 
glutamate concentration level in the SN, but the changes in concentration 
were not significant at group level. No substantial differences were found 
in any of the other investigated regions.  
SVS only affected GABA concentrations in the SN. The GABA reuptake 
inhibitor, NNC 711, was included in the perfusion fluid to detect rapid 
increases of GABA. There is a possibility that the addition of this reuptake 
inhibitor could prolong the increases of GABA concentrations and cause 
secondary changes in network activity. However, significant increase of 
GABA was not found in any of the other investigated regions, and was 
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selective to the SN.  The increased mean values of glutamate and glycine 
in the SN suggest that SVS can affect other neurotransmitters in the in-
vestigated regions and this possibility cannot be disregarded as re-uptake 
inhibition may be needed to detect physiological changes in amino acid 
neurotransmitter release. Furthermore, microdialysis during SVS in oth-
er related regions such as the STN, might give a broader understanding of 
its effects in dopamine related disorders. The STN is important for par-
kinsonian symptoms as demonstrated by STN-DBS, and high frequency 
stimulation of STN has demonstrated increased release of nigral GABA 
and glutamate in the rat brain [133].   
In 6-OHDA hemilesioned animals there was a steady increase of GABA 
concentration in both ipsilesional and contralesional SN after levodopa 
injection. Similar concentrations of GABA could be measured in the ipsi-
lesional SN after SVS, Fig 6A.    
An increase of GABA in the SN counteracts parkinsonian symptoms by 
disinhibiting the activation of specific regions in the basal ganglia. An 
interesting outcome is that while levodopa increased dopamine concen-
trations in the SN (the striatum was not investigated), SVS did not alter 
dopamine concentrations in any of the regions investigated, Fig 6B. As 
SVS also increased nigral GABA, it seems that SVS may share some fea-
tures with levodopa. However the lack of increased dopamine levels after 
SVS leads to the assumption that SVS mediates nigral GABA release 
through a different mechanism than the dopaminergic system. Another 
finding was that SVS appeared to alter GABA concentrations differently 
in the ipsi- and contralesional SN in the 6-OHDA lesioned animals. So, 
despite the bilateral nature of the stimulation, GABA concentrations in-
creased on the ipsilesional side while they decreased on the contralesion-
al side. The result being that SVS appeared to balance out the absolute 
levels of GABA in the SN. In contrast, levodopa induced a parallel in-
crease of GABA on both sides. Similarly, there was an increase of dopa-
mine levels on both sides, although higher levels were observed on the 
ipsilesional side.   
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Figure 6 GABA and dopamine (DA) concentrations (nM, mean±SEM) in the ipsi- and contralesional SN 
of hemilesioned 6-OHDA animals following SVS and Levodopa treatment. Panel A shows the GABA 
concentrations and panel B the simultaneous DA concentrations, during day 1 and day 2. NNC 711 (30 
µM) was present throughout the experiment and left in the microdialysis tube that was re-sealed over 
night. SVS treatment is indicated by a horisontal bar, and the levodopa injection by an arrow. 
 
Symptoms in PD that do not respond well to levodopa could stem from 
dysfunctional activity involving neurotransmitters such as GABA, nora-
drenaline, serotonin and glutamate [134]. Efferent GABAergic neurons 
and glutamate are not only found in the striatum, but interneurons are 
also expressed widely throughout the entire brain [135]. Locus ceruleus, 
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part of the brain stem, is a main area mediating noradrenergic neurons 
which project to widespread areas of the brain and spinal cord [136]. One 
of the major serotonergic nuclei is the raphe nuclei, projecting to many 
parts of the brain but appear to mainly involve the sensory, motor and 
limbic systems [137]. SVS could affect motor control through altered ac-
tivity in the SN by involving a non-dopaminergic pathway, perhaps in-
volving the cerebello-thalamo-cortical circuit.   
In paper II, we failed to observe any c-Fos expression in the SN after SVS 
or levodopa. Previous studies have also demonstrated very little to no c-
Fos expression in the SN of non-dyskinetic hemilesioned rats [138-140]. 
This is more or less expected as treatments that increase GABA release in 
the SNr will inhibit the activity in this region. The region which projects 
directly to the SNr is the CPu, and SVS induced a similar level of c-Fos 
activation in this region, in both shamlesioned and 6-OHDA hemi-
lesioned animals. Saline did not induce any activation in the CPu. In the 
6-OHDA hemilesioned animals, levodopa appeared to induce a higher 
level of c-Fos activation in the ipsilesional side than did SVS. However, 
there were no significant differences. Consistent with the findings of pa-
per I, we did not find any significant c-Fos activation in the PPN or the 
VM either. In the STN, some c-Fos expression could be observed, alt-
hough no group-specific differences were found. Overall, SVS activated a 
number of regions in the brain aside from the CPu, which overlapped 
with a single dose of levodopa but not saline. These regions were: the in-
termediate nucleus of lateral lemniscus (ILL) and ventrolateral medullary 
region (RVLM). Two regions that did differ in c-Fos expression as an ef-
fect of SVS or levodopa were the MVePC and the LHb. Activation in the 
MVePC following SVS was expected as it is the primary recipient of ves-
tibular stimulation.    
Levodopa did not induce any substantial c-Fos expression in the MVePC 
of either 6-OHDA hemilesioned or shamlesioned animals. SVS on the 
other hand induced significantly more c-Fos expression in the 6-OHDA 
animals than levodopa did. Interestingly, SVS also increased c-Fos ex-
pression significantly more in 6-OHDA animals than it did in sham-
lesioned animals. This is in agreement with the theory that vestibular 
activity is downregulated by dopamine depletion. It also supports the ev-
idence which indicate that the activity or responsiveness of MVePC neu-
rons is decreased in PD [141-144]. A possible explanation to improved 
balance responses in PD during SVS is therefore that SVS ameliorate the 
decreased responsiveness.       
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One region that we did not anticipate any activity in was the LHb. How-
ever, in both 6-OHDA hemilesioned and shamlesioned animals we found 
significant c-Fos expression here after SVS, but very little after levodopa 
and not at all after saline. The habenula nucleus is part of the epithala-
mus and located close to the midline. It consists of two subnuclei, the 
medial and the lateral habenula [145]. In recent years, research has 
pointed to neurocommunication between the LHb and the pre-frontal 
cortex, parts of the basal ganglia and the hypothalamus. It has been sug-
gested that the LHb receives both GABA and glutamate inputs, and have 
a modulating effect not only on dopaminergic system, but also the sero-
tonergic and noradrenergic systems [146]. Activation in this region plays 
a big part in reward behaviour and response to aversive stimuli. It is like-
ly to be involved in modulation of symptoms including depression, sleep 
disturbances, spatial awareness and autonomic decision-making as well 
as failure in associative learning [145, 147-149]. Furthermore, LHb may 
be involved in inhibiting dopamine neurons directly and have an excita-
tory effect through projections to the VTA [149].  
Many of the symptoms linked with LHb regulation are associated with 
PD and ADHD. Interestingly, behaviours that appear to be modulated by 
the LHb are some of the symptoms in PD which do not respond aptly to 
levodopa medication [5]. Albeit some of these symptoms, such as sleep 
disturbances, are hypothesised to have a dopaminergic component [150], 
they may not be solitarily dopamine regulated. It is known that the basal 
ganglia circuitry plays a crucial part in parkinsonian and dyskinetic dis-
orders. The roles of other subcortical regions and their interplay of excita-
tory and inhibitory neurotransmission to/from the basal ganglia are less 
established in regard to these disorders. Newer findings have shown an 
increased level of activity in the LHb during levodopa-induced dyskine-
sia, and inhibition of this region reduced these abnormal involuntary 
movements in 6-OHDA rats [151]. Furthermore, a 6-OHDA hemilesion in 
the SN of rats was found to change GABA transmission in the LHb, and 
regulation of GABA receptors through injection of a GABA agonist in the 
LHb produced anti-depressive effects [152]. Also, high-frequency stimu-
lation of the STN have been found to alter activity in the LHb in rats, and 
it has been proposed that this region may mediate some of the neuropsy-
chiatric symptoms in PD, such as depression [153].  
We propose that the mechanism behind SVS involves inhibition of the 
overactive SNr though an increase of GABA transmission in the nigrostri-
atal circuit. This process appears to be mainly non-dopaminergic, alt-
 
 
2 0 1 7  
GHAZALEH SAMOUDI  
46 
hough some of the brain regions induced by SVS activation overlap with 
the activity observed after levodopa. Given the influence SVS has on the 
habenula, it is possible that SVS through its mediation on the non-
dopaminergic pathway could have positive effects on the neuropsychiat-
ric symptoms of PD. Consequently, future studies could explore the ef-
fects of SVS on such dysfunctions in PD, including depression, anxiety, 
apathy, fatigue and psychotic symptoms.   
An interesting aspect to consider for future studies could be to look at the 
activation pattern in the medial and lateral part of the habenula separate-
ly. In our findings there appeared to be differences in the pattern activat-
ed, with c-Fos expression across the entire LHb in some animals and only 
in the medial or lateral part in other animals.     
The main limitation of paper II was the lack of a sham-stimulated control 
group with implanted electrodes. Thus, it is not possible to discount pos-
sible effects of wearing the electrodes. Furthermore, there may have been 
some carry-over effects of the threshold determination, although this 
would have affected both the 6-OHDA and shamlesioned animals.  
 
Effects of SVS on motor functions 
In paper I, the overall time spent on the rotarod during treatment 
(SVS/sham SVS or levodopa/saline) was compared to a baseline meas-
urement during that same day, to avoid day to day performance bias. 
There was no effect of the treatment order/treatment day, as an ANOVA 
with treatment and trial day as independent factors revealed. During the 
SVS treatment 6-OHDA hemilesioned animals improved their perfor-
mance on the rod compared to the sham SVS treatment. The levodopa 
treatment did not improve the overall performance on the rod compared 
to saline. However, when looking more closely at the performance of in-
dividual animals, levodopa had an improving effect similar to the SVS 
outcome in half of the animals, while it impaired performance in the oth-
er half. Thus, there were positive and negative responders to levodopa 
treatment. Perhaps the bilateral increase of nigral GABA after levodopa 
explains this inconsistent rotarod performance. As levodopa increases 
nigral GABA in a parallel fashion, it may not reduce the imbalance in lo-
comotor functions. SVS, however, improved overall locomotion on the 
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rotarod in all lesioned animals. This supports the theory of a rebalancing 
effect in locomotion, consistent with the more balanced GABA release 
between SN on the ipsi- and contralesioned side. In the sham hemi-
lesioned animals, no significant effect of SVS could be found as animals 
performed no better or worse during SVS than during sham SVS. Conse-
quently, the impaired brain (6-OHDA hemilesion) appears to improve 
more after noisy stimulation than does a normally working brain (sham 
hemilesion). 
On the Montoya staircase test, we evaluated the effects of SVS on fine 
motor skills by assessing number of pellets picked up on either lesioned 
or intact side. The procedure was similar to the rotarod testing, however 
while animals received 30 minutes of SVS/sham SVS, testing continued 
without stimulation. The reason for this procedure was that the electrode 
wires did not allow free movement in the test-box and therefore hindered 
the performance.  
Animals with a 6-OHDA-hemilesion had poorer performance and picked 
up fewer pellets with the contralesional forelimb compared to the ipsile-
sional forelimb. This was expected as a 6-OHDA hemilesion leads to 
poorer ability to use the contralesional side, something that is visible 
mainly on forelimb use. There were no effects of SVS on forelimb use in 
either the 6-OHDA or the sham hemilesioned animals.  
One of the primary results of paper I was that SVS has an enhancing ef-
fect on locomotion, but this enhancing effect does not appear to affect 
fine motor skills. As the vestibular pathways have a modulating effect on 
axial motor systems, it is possible that SVS mainly, or at least initially, 
affects posture, balance and locomotion rather than the appendicular mo-
tor system. In a subgroup of PD patients and in advanced PD (Hoehn and 
Yahr >3), balance and other modalities which are affected by axial func-
tion often do not respond satisfactory to levodopa medication [5]. Addi-
tionally, STN-DBS is limited in improving these particular symptoms 
[154], possibly supporting the theory of a non-dopaminergic pathology 
behind these postural difficulties [155]. STN-DBS in combination with 
high-frequency DBS of the SNr have been found to improve axial symp-
toms and gait, something that could not be achieved with STN-DBS alone 
[156]. Given that both DBS-SNr and SVS inhibit the overactive SNr, eval-
uating SVS as an add-on therapy in PD patients with a predominance of 
axial symptoms is an attractive possibility.   
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In paper III, we attempted to evaluate the effect of short-term SVS on 
posture and locomotion in a clinical trial. Participants were treated with 
SVS or sham SVS on separate days for a maximum of 3h in a cross-over 
design. On each occasion an acute levodopa (200 mg) challenge was per-
formed after initial assessments in their worst OFF-condition after an 
overnight pause of medication.  
SVS improved the time it took for participants to correct a forced 
pull/release motion in the dynamic balance test. Off medication, SVS  
further reduced the centre of pressure (COP) deviations in mediolateral 
correction and in backward correction. In the static balance test, SVS re-
duced the centre of pressure sway-path compared to sham SVS. Sway-
path was also reduced with SVS when participants stood on a foam mat-
tress. This effect was only found off medication. Medication had no sig-
nificant effect on postural responses. It did however have a main effect on 
UPDRS-III scores and on PLM times. In several patients, the PLM times 
improved after levodopa treatment during SVS compared to sham SVS, 
although the improvements were not statistically significant. Further-
more, there was an interaction between the effects of medication and SVS 
on the UPDRS-III scores, with lower scores during the off medication 
state. Albeit small improvements were observed, these finding suggest 
that the recovery after a postural perturbation as well as overall postural 
control improved with SVS. Interestingly, the enhancing effect of SVS was 
found primarily during the off medication state. This was true for most 
assessments, even where SVS did not significantly improve function there 
were interactions with medication, suggesting larger effect off medica-
tion. 
A reduced vestibulocollic reflex has previously been found in PD patients, 
and levodopa was shown to normalise this impairment [142]. The de-
creased sway-path found during SVS was greatest when standing on a 
foam mattress blindfolded. This condition reduces the proprioceptive 
input from the limbs and without visual input the subject has to rely more 
on the vestibular system. Near threshold SVS could by increasing the re-
sponsiveness of a supressed vestibular system enhance the impaired ves-
tibulospinal responses in PD.  
Our observation that levodopa medication had little substantial effect on 
both dynamic and static balance control is consistent with previous find-
ings [157]. While dopaminergic medications successfully decrease stiff-
ness, they can often lead to dyskinesia, which could have negative effect 
 
 
 
 
RESULTS & DISCUSSION  
49 
on overall postural balance [158]. Dopaminergic medication primarily 
enhances appendicular motor symptoms, leaving axial motor dysfunc-
tions less improved. It is possible that SVS could be used to target these 
symptoms, in particular balance and gait difficulties.  
Noisy vestibular stimulation has the potential to increase or decrease cor-
tical excitability depending on the frequency used [159]. This may en-
hance or disrupt atypical cortical as well as subcortical oscillatory activity, 
thereby possibly improving motor behaviour [160, 161]. We used a near-
threshold stimulation paradigm, where the maximum current was deter-
mined based on subjective and/or objective observation of rhythmic 
stimulation. The stimulation currents applied (mean amplitude = 0.4 - 
0.5 mA) were similar to currents in other clinical trials (mean amplitude 
= 0.1 – 0.4 mA) where improvements in balance and motor function were 
found [112, 127, 162]. As the clinical evaluations were based on a small 
pilot study (n=10), the outcomes should be interpreted with caution. 
Larger studies are required for assessing the clinical relevance, and the 
long term effects of near threshold SVS on motor improvement.        
 
SVS in relation to levodopa  
The interactions and differences between SVS and levodopa on motor 
functions and neurotransmission have already been reported in previous 
chapters of this thesis. Some adverse events were however reported in 
study III.  
There was one report of mild headache and nausea during active SVS and 
similarly one report of slight vertigo during sham SVS (but not active 
SVS). In combination with levodopa, there was one report of slight nau-
sea. One participant experienced slight nausea during sham SVS after 
levodopa, but had more severe nausea during SVS in combination with 
levodopa with two incidents of vomiting. The single dose of levodopa was 
the same for all participants (200mg) and was higher than the standard 
dose this participant was used to.  
None of the participants was able to distinguish whether SVS was active 
or not. Furthermore, none of the participants in either study reported any 
significant discomfort during SVS alone. A potential for worsening of 
medication evoked nausea with SVS is however noted, and may be taken 
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into consideration in future clinical trials. In conclusion, we found short 
term treatment with SVS was safe in an adult population with PD and in a 
mixed population with ADHD off medication. 
 
Effect of SVS on cognitive performance in ADHD 
It has been reported that galvanic vestibular stimulation can activate 
multisensory cortical areas, including temporoparietal cortex, basal gan-
glia, and anterior cingulated gyrus [163], as well as the hippocampus 
[164], indicating a relationship between the vestibular system and 
memory. The role of SVS in spatial memory and cognitive performance in 
ADHD has not been tested before.  
Although we found a trend toward better spatial memory in ADHD, we 
did not find support for improved cognitive performance in paper IV. 
Treatment improved the number of correct series carried out as well as 
number of correctly indicated markers within a series in the span-board 
task. The primary outcome of overall correctly indicated markers was 
however not affected by SVS treatment. Furthermore, no treatment ef-
fects were found in the word-recall test or the flower trail tests.  
An important reason for trying out SVS in ADHD are the recent observa-
tions that acoustic white noise improves performance in the word-recall 
test and the Span-board task in children with ADHD, where noise benefit 
was greater without the combination of medicine on word recall, but 
equally beneficial with or without medication in the Span-board task 
[90]. The findings in our pilot study indicate that SVS, without the com-
bination of medication does not induce similar positive effects on cogni-
tive performance as auditory noise. As we have found changes in 
neurochemistry as well as improvement in motor function (paper I) and 
postural control (paper III) during this particular configuration, a more 
prominent outcome was expected if indeed any effects were present. 
Noise modality could be of importance, suggesting that any kind of sto-
chastic noise will not have effect. It is also possible that the near thresh-
old amplitude of the stimulus applied was not appropriate for assessing 
short-term verbal memory or visuo-spatial working memory.  
Noisy vestibular stimulation has improved cognitive ability in a number 
of previous studies. In an animal study, rats with an induced cognitive 
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impairment performed better on the Morris Water Maze task after noisy 
vestibular stimulation [165]. However, cognitive improvements were not 
apparent after 1 session, but only observed after repetitive stimulation (5 
sessions). In stroke patients with hemi-spatial neglect, repetitive noisy 
galvanic vestibular stimulation induced long-term improvements on lat-
eral attention. The participants performance increased after 1, 5 or 10 
sessions of noisy stimulation [117]. However, the mean amplitude (1 mA) 
was higher than the near threshold protocol used in our study, and could 
be one reason for the contrasting outcome. Furthermore persons with 
ADHD do not have a neglect problem. 
One difference between our study and the mentioned previous findings of 
SVS on cognitive performance was that we only applied the stimulation 
for a short period of time (approximately 1h) and all testing was done 
during this time. A larger study population, specifically with ADHD sub-
types in separate study groups, could provide a more representative out-
come of the role of SVS on cognitive performance. It is also possible that 
other indices of higher function could benefit from noise.  
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CONCLUSION 
We suggest that short-term application of SVS influences motor control 
by a dopamine independent disinhibition of the basal ganglia output. The 
effects are thus far modest in a clinical setting.  Short-term application of 
SVS has, in the configurations used, failed to improve cognitive perfor-
mance significantly in ADHD, the cognitive effects in PD have not been 
assessed in this thesis. Long-term application may affect behavioural out-
comes differently. We have found that near threshold SVS mainly leads to 
activity in specific areas of the vestibular nuclei and the LHb, areas where 
levodopa leads to a slight activation and saline fails to activate all togeth-
er. Furthermore, SVS and levodopa induced similar activity patterns in 
some key regions where the negative saline control did not, including the 
striatum, the ILL and RVLM. These similarities in activation pattern dur-
ing SVS and levodopa treatment may explain some of the motor en-
hancements observed in both preclinical and clinical studies. However, 
while levodopa mainly affects the nigrostriatal pathway, SVS could have a 
larger influence on a non-dopaminergic pathway, possibly including an 
increased transmission through the LHb. In PD, enhancement of vestibu-
lar function could also indirectly improve motor symptoms important in 
balance and gait.  
Further studies may add more specific clues to how vestibular stimula-
tion functions and perhaps illuminate the pathway it activates. This could 
give indications to which behaviours that are mainly affected by its appli-
cation. The available data suggest that PD patients with axial symptoms 
that respond less to levodopa medication and/or report falls may be more 
likely to benefit from SVS and it would therefore be of interest to study 
long-term use of SVS in this population. 
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